# OnCo record epibiologics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/epibiologics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "epibiologics" ;
  schema:name "EpiBiologics"@en ;
  schema:description "EpiBiologics makes two-armed antibodies that drag a harmful protein on the outside of a cell into the cell's own disposal system, so the protein is destroyed rather than just blocked. Its first medicine, EPI-326, is being tested in lung and head and neck cancers driven by EGFR."@en ;
  schema:url <https://onco.cc/companies/epibiologics/>, <https://www.epibiologics.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.epibiologics.com/>, <https://www.epibiologics.com/news-publications/epibiologics-closes-107m-series-b-to-advance-pipeline-of-novel-bispecific-antibodies-to-selectively-degrade-extracellular-protein-targets-in-oncology-and-immunology>, <https://www.epibiologics.com/news-publications/epibiologics-doses-first-patient-with-epi-326-bispecific-antibody-in-global-phase-1-study-for-egfr-driven-solid-tumors>, <https://clinicaltrials.gov/study/NCT07462377> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/egfr/> .